{"id":"W4231713150","doi":"10.1182/blood.v124.21.3095.3095","title":"Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Brentuximab vedotin; Medicine; Internal medicine; Anaplastic large-cell lymphoma; Population; Refractory (planetary science); Oncology; Phases of clinical research; Chemotherapy regimen; CD30; Lymphoma; Surgery; Clinical trial; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003798109,0.0009271951,0.001496517,0.0003237706,0.0004661321,0.0009507231,0.0006919311,0.0009030694,0.003177047],"category_scores_gemma":[0.002004317,0.0002825742,0.001299269,0.0004067555,0.0003849785,0.0007637878,0.0004720479,0.002199417,0.0007291819],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006520912,"about_ca_system_score_gemma":0.0008061539,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000638407,"about_ca_topic_score_gemma":0.001470969,"domain_scores_codex":[0.999077,0.0005088512,0.00007241081,0.0001126271,0.000123104,0.0001060014],"domain_scores_gemma":[0.9980043,0.0005191189,0.0004673803,0.0001848011,0.0002229352,0.000601419],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7218153,0.02086683,0.06453688,0.001741361,0.00494621,0.0006252985,0.0005570103,0.004407031,0.03083819,0.0002880965,0.01815901,0.1312189],"study_design_scores_gemma":[0.3022602,0.4259005,0.2377827,0.0002240682,0.004046054,0.001194069,0.0002175686,0.002762805,0.00585845,0.0004594277,0.01919435,0.00009982499],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9836305,0.005178081,0.0006807423,0.0005642694,0.0001067934,0.001213202,0.005707156,0.00004983028,0.002869422],"genre_scores_gemma":[0.9781917,0.002360422,0.0007566382,0.0008206669,0.0001514538,0.001415337,0.01449677,0.00002413786,0.001782839],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003798109,"threshold_uncertainty_score":0.02008659,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02174638280430107,"score_gpt":0.2677405028815592,"score_spread":0.2459941200772581,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}